Zynerba Pharmeceuticals

General Information

We are a ten-year-old specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Our management team is highly experienced and has a successful history of development, regulatory approval and commercialization of patch and gel transdermal delivery products. We are evaluating two patent-protected product candidates, ZYN002 and ZYN001, in five indications. We intend to study ZYN002 in patients with refractory epilepsy, Fragile X syndrome, or FXS, and osteoarthritis, or OA. We intend to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Employees: 7
Founded: 2007
Contact Information
Address 80 W. Lancaster Avenue, Suite 300, Devon, PA 19333 (484), US
Phone Number (484) 581-7505
Web Address http://www.zynerba.com
View Prospectus: Zynerba Pharmeceuticals
Financial Information
Market Cap $122.3mil
Revenues $0.7 mil (last 12 months)
Net Income $-6.9 mil (last 12 months)
IPO Profile
Symbol ZYNE
Exchange NASDAQ
Shares (millions): 3.0
Price range $14.00 - $14.00
Est. $ Volume $42.0 mil
Manager / Joint Managers Jefferies/ Piper Jaffray
CO-Managers Canaccord Genuity/ Oppenheimer & Co.
Expected To Trade: 8/5/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change